Skip to main content
Top
Published in:

01-04-2023 | Interferon | Case report

Natalizumab

Progressive multifocal leukoencephalopathy: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Karanasios P, et al. Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study 'TOPICS greece'. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7: No. 3, Jul-Sep 2021. Available from: URL: https://journals.sagepub.com/doi/10.1177/20552173211035803 Karanasios P, et al. Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study 'TOPICS greece'. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7: No. 3, Jul-Sep 2021. Available from: URL: https://​journals.​sagepub.​com/​doi/​10.​1177/​2055217321103580​3
Metadata
Title
Natalizumab
Progressive multifocal leukoencephalopathy: 2 case reports
Publication date
01-04-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38190-4

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Sodium-chloride

Case report

Antineoplastics

Case report

Tranexamic-acid